Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Depreciation & Amortization (CF) (2020 - 2025)

Historic Depreciation & Amortization (CF) for Apellis Pharmaceuticals (APLS) over the last 6 years, with Q3 2025 value amounting to $339000.0.

  • Apellis Pharmaceuticals' Depreciation & Amortization (CF) fell 2582.06% to $339000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year decrease of 810.51%. This contributed to the annual value of $1.8 million for FY2024, which is 72.87% up from last year.
  • Apellis Pharmaceuticals' Depreciation & Amortization (CF) amounted to $339000.0 in Q3 2025, which was down 2582.06% from $446000.0 recorded in Q2 2025.
  • In the past 5 years, Apellis Pharmaceuticals' Depreciation & Amortization (CF) ranged from a high of $476000.0 in Q4 2023 and a low of $282000.0 during Q1 2021
  • For the 5-year period, Apellis Pharmaceuticals' Depreciation & Amortization (CF) averaged around $407526.3, with its median value being $425000.0 (2023).
  • As far as peak fluctuations go, Apellis Pharmaceuticals' Depreciation & Amortization (CF) skyrocketed by 36526.32% in 2021, and later plummeted by 2582.06% in 2025.
  • Quarter analysis of 5 years shows Apellis Pharmaceuticals' Depreciation & Amortization (CF) stood at $373000.0 in 2021, then grew by 4.02% to $388000.0 in 2022, then rose by 22.68% to $476000.0 in 2023, then fell by 6.09% to $447000.0 in 2024, then decreased by 24.16% to $339000.0 in 2025.
  • Its Depreciation & Amortization (CF) stands at $339000.0 for Q3 2025, versus $446000.0 for Q2 2025 and $446000.0 for Q1 2025.